# US 2025/0018056 A1 · Strategies for knock-ins at c3 safe harbor sites

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0018056 A1
- Document ID: US20250018056A1
- Status: Published application
- Kind: A1
- Application number: 18/549,791
- Filed: 2022-03-10
- Published: 2025-01-16
- Earliest claimed: 2021-03-11
- Assignees: EmendoBio Inc.
- Applicants: EmendoBio Inc.
- Inventors: Rafi Emmanuel; Michal Golan Mashiach; Joseph Dicken
- Web page: https://patentgrep.com/patent/US20250018056A1

## CPC

- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- C07K 14/472: {Complement proteins, e.g. anaphylatoxin, C3a, C5a}
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- C12N 15/902: {using homologous recombination}
- A61K 35/407: Liver; Hepatocytes
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 2310/10: Type of nucleic acid
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2510/00: Genetically modified cells
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

RNA molecules comprising a guide sequence portion having 17-50 contiguous nucleotides in the sequence set forth in any one of SEQ ID NOs: 1-7,046 and compositions, methods, and uses thereof.

## Claims

### Claim 1

A method for modifying in a cell an allele of the Complement component 3 (C3) gene, the method comprising
introducing to the cell a composition comprising:
at least one CRISPR nuclease or a nucleotide sequence encoding a CRISPR nuclease; and
a RNA molecule comprising a guide sequence portion having 17-50 nucleotides or a nucleotide sequence encoding the same,
wherein a complex of the CRISPR nuclease and the RNA molecule affects a double strand break in the allele of the C3 gene.

### Claim 2 (depends on 1)

The method of claim 1, wherein the composition further comprises a donor molecule containing a sequence of nucleotides that is introduced at the double strand break site such that the expression of the introduced sequence of nucleotides is mediated by the promoter of the C3 gene.

### Claim 3 (depends on 2)

The method of claim 2, wherein the introduced sequence is a sequence from a ATP7B, A1AT, G6PC, SERPINA, LDLR, TTR, ornithine transcarbamylase, argininosuccinic acid synthetase, arginase, argininosuccinase, carbamoyl phosphate synthetase, and N-acetylglutamate synthetase, Alpha Galactosidase A, Coagulation Factor IX, Coagulation Factor VII, Lysosomal Alpha Glucosidase, Fibrinogen, Phenylalanine 4 Hydroxylase, Alkaline Phosphatase, Glucosylceramidase, Beta Galactosidase, Porphobilinogen Deaminase, Arylsulfatase B, Beta Glucuronidase, Alpha N Acetylglucosaminidase, Lysosomal Alpha, Alpha L-Iduronidase, Mannosidase, Phosphatidylcholine Sterol Acyltransferase, N-Sulphoglucosamine Sulphohydrolase, Coagulation Factor X, N-Acetylgalactosamine-6-Sulfatase, Sphingomyelin Phosphodiesterase, A1AT, Iduronate-2-Sulfatase, Lysosomal Alpha Glucosidase, Cyclin Dependent Kinase Like 5, Prolow Density Lipoprotein Receptor Related Protein 1, Phenylalanine Ammonia Lyase, Protein Glutamine Gamma Glutamyltransferase K, or Lysosomal Protective Protein encoding gene.

### Claim 4 (depends on 1)

The method of claim 1, wherein the guide sequence portion of the RNA molecule targets the CRISPR nuclease to a SNP position of a C3 allele.

### Claim 5 (depends on 4)

The method of claim 4, wherein the SNP position is any one of rs17030, rs199713383, and rs35473940, and/or wherein the SNP position contains a heterozygous SNP.

### Claim 6 (depends on 1)

The method of claim 1, wherein the guide sequence portion of the RNA molecule comprises 17-50 contiguous nucleotides containing nucleotides in the sequence set forth in any one of SEQ ID NOs: 1-7,046 that targets a SNP position of a C3 allele.

### Claim 7

(canceled)

### Claim 8 (depends on 1)

The method of claim 1, wherein the RNA molecule comprises a non-discriminatory guide sequence portion that targets Intron 1 of C3 or a 3′ untranslated region (3′ UTR) of C3, and/or wherein the RNA molecule comprises a non-discriminatory guide portion that targets a sequence that is located within a genomic range selected from any one of 19:6677732-6677881 and 19:6719404-6720515.

### Claim 9

(canceled)

### Claim 10 (depends on 1)

The method of claim 1, wherein the guide sequence portion of the RNA molecule comprises 17-50 contiguous nucleotides containing nucleotides in the sequence set forth in any one of SEQ ID NOs: 1-7,046, and/or wherein the guide sequence portion of the RNA molecule comprises 1, 2, 3, 4, or 5 nucleotide mismatches relative to a fully-complementary C3 target sequence.

### Claim 11

(canceled)

### Claim 12 (depends on 1)

The method of claim 1, wherein the guide sequence portion of the RNA molecule comprises 17-50 contiguous nucleotides containing nucleotides in the sequence set forth in any one of SEQ ID NOs: 1-7,046 modified to contain 1, 2, 3, 4, or 5 nucleotide mismatches relative to a fully-complementary C3 target sequence, and/or wherein the guide sequence portion provides higher targeting specificity to the complex of the CRISPR nuclease and the RNA molecule relative to a guide sequence portion that has higher complementarity to an allele of the C3 gene.

### Claim 13

(canceled)

### Claim 14 (depends on 1)

A modified cell obtained by the method of claim 1.

### Claim 15 (depends on 14)

The method of claim 14, wherein the modified cell is a stem cell, liver cell, hepatocyte, or iPS-derived hepatocyte.

### Claim 16

An RNA molecule comprising a guide sequence portion having 17-50 contiguous nucleotides containing nucleotides in the sequence set forth in any one of SEQ ID NOs: 1-7,046, or SEQ ID NOs: 1-7,046 modified to contain 1, 2, 3, 4, or 5 nucleotide mismatches relative to a fully-complementary C3 target sequence.

### Claim 17 (depends on 16)

A composition comprising the RNA molecule of claim 16 and at least one CRISPR nuclease.

### Claim 18 (depends on 17)

The composition of claim 17, further comprising a donor molecule.

### Claim 19 (depends on 18)

The composition of claim 18, wherein the donor molecule contains a sequence from a ATP7B, A1AT, G6PC, SERPINA, LDLR, TTR, ornithine transcarbamylase, argininosuccinic acid synthetase, arginase, argininosuccinase, carbamoyl phosphate synthetase, N-acetylglutamate synthetase, Alpha Galactosidase A, Coagulation Factor IX, Coagulation Factor VII, Lysosomal Alpha Glucosidase, Fibrinogen, Phenylalanine 4 Hydroxylase, Alkaline Phosphatase, Glucosylceramidase, Beta Galactosidase, Porphobilinogen Deaminase, Arylsulfatase B, Beta Glucuronidase, Alpha N Acetylglucosaminidase, Lysosomal Alpha, Alpha L-Iduronidase, Mannosidase, Phosphatidylcholine Sterol Acyltransferase, N-Sulphoglucosamine Sulphohydrolase, Coagulation Factor X, N-Acetylgalactosamine-6-Sulfatase, Sphingomyelin Phosphodiesterase, A1AT, Iduronate-2-Sulfatase, Lysosomal Alpha Glucosidase, Cyclin Dependent Kinase Like 5, Prolow Density Lipoprotein Receptor Related Protein 1, Phenylalanine Ammonia Lyase, Protein Glutamine Gamma Glutamyltransferase K, or Lysosomal Protective Protein encoding gene.

### Claim 20 (depends on 18)

A method for modifying a C3 allele in a cell, the method comprising delivering to the cell the composition of claim 18.

### Claim 21 (depends on 17)

A method for treating a disorder, the method comprising delivering to a cell of a subject having the disorder the composition of claim 17.

### Claim 22

(canceled)

### Claim 23

(canceled)

### Claim 24

(canceled)

### Claim 25 (depends on 21)

The method of claim 21, wherein the disorder is a liver-related disorder or a lysosomal storage disorder.

### Claim 26

(canceled)

### Claim 27 (depends on 14)

A method for treating a disorder, the method comprising delivering to the subject the modified cell of claim 14.

### Claim 28 (depends on 27)

The method of claim 27, wherein the disorder is a liver-related disorder or a lysosomal storage disorder.
